On Monday, Shares of SandRidge Energy, Inc. (NYSE:SD), lost -0.85% to $1.17, hitting its lowest level, after the company’s credit rating was reduced to CCC+ from B by Standard & Poor’s Ratings Services following the company’s debt-share swap.
The Oklahoma City-based oil and gas company said in a regulatory filing that it is exchanging stock with a single shareholder for a combined $50 million of its 7.5 percent notes maturing in March 2021 and its 8.125 percent notes due in October 2022.
SandRidge Energy, Inc., an oil and natural gas company, explores for and produces oil and natural gas properties primarily in the Mid-Continent region of the United States. The company operates through three segments: Exploration and Production, Drilling and Oil Field Services, and Midstream Services.
Shares of Twitter, Inc. (NYSE:TWTR), inclined 0.49% to $37.28, during its last trading session.
President Barack Obama is racking up the followers after the first presidential Twitter account was launched.
This isn’t Obama’s first presence on Twitter. Organizing for Action, a nonprofit that advocates for the agenda of Obama, has been tweeting since March 2007 as @BarackObama, with tweets from Obama himself signed as “-bo”. Marketwatch Reports.
Twitter, Inc. operates as a global platform for public self-expression and conversation in real time. It offers various products and services for users, counting Twitter that allows users to create, distribute, and discover content; and Vine and video, a mobile application that enables users to create and distribute short looping videos.
At the end of Monday’s trade, Shares of Merck & Co. Inc. (NYSE:MRK), lost -0.37% to $60.01.
Merck & Co., known as MSD outside the United States and Canada, declared recently that Adam Schechter, executive vice president and president, Global Human Health, Merck, is planned to present at the UBS 2015 Global Healthcare Conference in New York on May 19, 2015 at 10:30 a.m. EDT.
Merck & Co., Inc. provides health care solutions worldwide. The company offer therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases.
Finally, Oncothyreon Inc (NASDAQ:ONTY), ended its last trade with 6.58% gain, and closed at $2.59.
Oncothyreon Inc, has been on the move lately as the stock has risen by 39.7% in the past four weeks.
It is certainly encouraging that earnings estimates have risen in the past few weeks on the company, suggesting that sentiment on ONTY is moving in the right direction. In fact, the stock presently has a Zacks Rank #2 (Buy), suggesting that the recent run could certainly continue for this in-focus company.
Oncothyreon Inc., a clinical-stage biopharmaceutical company, engages in the research and development of therapeutic products for the treatment of cancer. Its clinical-stage product candidates comprise ONT-380, an orally active and selective small-molecule HER2 inhibitor, which is in two Phase 1b trials, one in combination with Kadcyla and another in combination with Xeloda and/or Herceptin; and ONT-10, a therapeutic vaccine in Phase 1 trial targeting the Mucin 1 peptide antigen (MUC1) for use in various cancer indications, counting breast, thyroid, colon, stomach, pancreas, ovarian, and prostate, in addition to certain types of lung cancer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
